NeuroMetrix, Inc. revealed that more than 2000 individuals suffering from fibromyalgia have been prescribed Quell Fibromyalgia since its launch in December 2022. This innovative device utilizes transcutaneous electrical nerve stimulation (TENS) to alleviate symptoms in patients with heightened pain sensitivity.
Quell Fibromyalgia employs wearable neuromodulation technology to target nerves in the upper calf with electrical pulses, effectively reducing lower extremity pain and other manifestations of fibromyalgia. This drug-free and non-invasive treatment can be personalized for each user, allowing for optimization through a convenient mobile app.
Individuals considering Quell Fibromyalgia should first consult with their healthcare provider to determine its suitability. It is important to note that the device is not recommended for those with certain implanted electronic devices or metal in close proximity. Patients can acquire Quell Fibromyalgia with a prescription and receive training on setup and calibration through the mobile app for at-home use.
NURO Stock Shows Positive Momentum Despite Trading Near Bottom: March 13, 2024 Analysis
On March 13, 2024, NURO stock showed signs of positive momentum as it traded near the bottom of its 52-week range and below its 200-day simple moving average. Despite these indicators, the stock price increased by $0.07 since the market last closed, representing a 1.83% rise.
NURO opened at $3.94 on this day, which was $0.03 higher than its previous close. This opening price indicated that there was some bullish sentiment surrounding the stock, as investors were willing to pay a slightly higher price to start the trading day.
While NURO may be trading near the bottom of its 52-week range and below its 200-day simple moving average, the positive price momentum on March 13, 2024, suggests that investors may be optimistic about the stock’s potential for growth in the near future. It will be interesting to see if this positive momentum continues in the days and weeks ahead, or if the stock will face resistance and potentially decline in value.
NURO Stock Performance Analysis: Mixed Results on March 13, 2024
On March 13, 2024, NURO stock experienced mixed performances based on the financial data provided by CNN Money. The company reported a total revenue of $5.90 million for the past year, which represented a 28.52% decrease compared to the previous year. However, there was a 9.52% increase in total revenue since the last quarter, with the company generating $1.32 million in revenue.
In terms of net income, NURO reported a net loss of $6.53 million for the past year, marking a 47.84% decrease from the previous year. In the last quarter, the company’s net loss was $1.65 million, showing no change from the previous quarter.
Earnings per share (EPS) also saw a decline for NURO stock. The company reported an EPS of -$6.27 for the past year, reflecting a 26.46% decrease from the previous year. In the last quarter, the EPS was -$1.08, which remained unchanged from the previous quarter.
Overall, NURO stock exhibited a mixed performance on March 13, 2024, with decreases in total revenue, net income, and EPS compared to the previous year. However, there were some improvements in total revenue since the last quarter, indicating a potential turnaround for the company. Investors should closely monitor NURO’s financial performance in the coming quarters to assess its long-term prospects.
